Research programme: adenosine A3 antagonists - Future Medicine
Alternative Names: A3AR antagonists - Future MedicineLatest Information Update: 28 Apr 2022
At a glance
- Originator Future Medicine
- Class Antiasthmatics; Antineoplastics; Antivirals; Eye disorder therapies; Hepatoprotectants; Nucleosides; Small molecules
- Mechanism of Action Adenosine A3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Cancer; Chronic obstructive pulmonary disease; Glaucoma; Middle East respiratory syndrome coronavirus; Non-alcoholic steatohepatitis; Pulmonary fibrosis; Renal failure; Zika virus infection
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Asthma in South Korea
- 28 Apr 2022 No recent reports of development identified for preclinical development in Cancer in South Korea
- 28 Apr 2022 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in South Korea
Development Overview
Introduction
Future Medicines is developing nucleoside conjugate-based adenosine A3 antagonists, for the treatment of glaucoma, renal disorders, non-alcoholic fatty liver disease (NASH), asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, middle east respiratory syndrome (MERS), Zika virus infections and cancer. Preclinical development is underway in South Korea.
One lead compound from the research programme, FM 101 [see Adis Insight Drug profile 800051460] is under preclinical development in South Korea, for the treatment of glaucoma.
As at April 2022, no recent reports of development had been identified for preclinical development in Asthma in South Korea, preclinical development in Cancer in South Korea, preclinical development in Chronic-obstructive-pulmonary-disease in South Korea, preclinical development in Glaucoma in South Korea, preclinical development in Middle-East-respiratory-syndrome-coronavirus in South Korea, preclinical development in Non-alcoholic-steatohepatitis in South Korea, preclinical development in Pulmonary-fibrosis in South Korea, preclinical development in Renal-failure in South Korea, preclinical development in Zika-virus-infection in South Korea.
Key Development Milestones
According to Future Medicine pipeline viewed in March 2018, preclinical development of adenosine A3 antagonists is underway for the treatment of glaucoma, renal disorders, non-alcoholic fatty liver disease (NASH), asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, middle east respiratory syndrome (MERS), Zika virus infections and cancer (Future Medicine pipeline, March 2018).
Patent Information
Future Medicine has been granted a Korean patent (Registration No. 10-1 323 413) entitled "Pharmaceutical compositions for preventing or treating chronic diseases including (2R,3R,4S)-2-(2- chloro -6-(3-Idobenzylamino)-9H- Purine -9-il)-Tetrahydrothiophene-3,4- Diol and its derivatives" [1] .
The company has also been granted two Korean patents (Registration No. 10-1 192 097 and 10-1 181 627) entitled "Pharmaceutical composition comprising A3 adenosine receptor agonist for treating colon cancer", and "Pharmaceutical composition comprising A3 adenosine receptor agonist for treating prostate cancer", respectively.
A Korean patent has been granted to Future Medicine (Registration No. 10-1 067 604) entitled "Novel selenonucleoside derivatives or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the same as an active ingredient".
Future Medicine was granted several Korean patents (Registration No. 10-0 971 296; 10-1 251 282 and 10-1 709 307) entitled "4'-selenonucleoside derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and phrmaceutical composition for the prevention and treatment of cancers containing the same as an active ingredient", "Sulfonamide derivative which suppresses prostaclandin synthesis and a pharmaceutical composition containing the same", and "The pharmaceutical compositions for the prevention and treatment of the nash, liver fibrosis and liver cirrhosis containing adenosine derivatives", respectively.
In addition, the company has been granted an international patent [0 901 8371 (USA); ZL 200 780 052 031.X (China); 05 306 238 (Japan); 2 007 348 394 (Australia); 02 142 549 (4 European countries); 2 680 179 (Canada); 7220/CHENP/2008 (India)] entitled "Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention, and treatment of the inflammatory diseases containing, the same as an active ingredient".
Drug Properties & Chemical Synopsis
- Formulation unspecified
- Class Antiasthmatics, Antineoplastics, Antivirals, Eye disorder therapies, Hepatoprotectants, Nucleosides, Small molecules
- Target Adenosine A3 receptor
- Mechanism of Action Adenosine A3 receptor antagonists
-
WHO ATC code
A05 (Bile and Liver Therapy)
G04 (Urologicals)
J05A-X (Other antivirals)
L01 (Antineoplastic Agents)
R03 (Drugs for Obstructive Airway Diseases)
S01E-X (Other antiglaucoma preparations)
-
EPhMRA code
A5 (Cholagogues and Hepatic Protectors)
G4 (Urologicals)
J5B9 (Antivirals, others)
L1 (Antineoplastics)
R3 (Anti-Asthma and COPD Products)
S1E (Miotics and Antiglaucoma Preparations)
Development Status
Summary Table
Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
---|---|---|---|---|---|---|---|
Asthma | - | - | No development reported (Preclinical) | South Korea | unspecified / unspecified | Future Medicine | 28 Apr 2022 |
Cancer | - | - | No development reported (Preclinical) | South Korea | unspecified / unspecified | Future Medicine | 28 Apr 2022 |
Chronic obstructive pulmonary disease | - | - | No development reported (Preclinical) | South Korea | unspecified / unspecified | Future Medicine | 28 Apr 2022 |
Glaucoma | - | - | No development reported (Preclinical) | South Korea | unspecified / unspecified | Future Medicine | 28 Apr 2022 |
Middle East respiratory syndrome coronavirus | - | - | No development reported (Preclinical) | South Korea | unspecified / unspecified | Future Medicine | 28 Apr 2022 |
Non-alcoholic steatohepatitis | - | - | No development reported (Preclinical) | South Korea | unspecified / unspecified | Future Medicine | 28 Apr 2022 |
Pulmonary fibrosis | - | - | No development reported (Preclinical) | South Korea | unspecified / unspecified | Future Medicine | 28 Apr 2022 |
Renal failure | - | - | No development reported (Preclinical) | South Korea | unspecified / unspecified | Future Medicine | 28 Apr 2022 |
Zika virus infection | - | - | No development reported (Preclinical) | South Korea | unspecified / unspecified | Future Medicine | 28 Apr 2022 |
Commercial Information
Involved Organisations
Organisation | Involvement | Countries |
---|---|---|
Future Medicine | Originator | South-Korea |
Future Medicine | Owner | South-Korea |
Development History
Event Date | Update Type | Comment |
---|---|---|
28 Apr 2022 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Asthma in South Korea Updated 28 Apr 2022 |
28 Apr 2022 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Cancer in South Korea Updated 28 Apr 2022 |
28 Apr 2022 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in South Korea Updated 28 Apr 2022 |
28 Apr 2022 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Glaucoma in South Korea Updated 28 Apr 2022 |
28 Apr 2022 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Middle-East-respiratory-syndrome-coronavirus in South Korea Updated 28 Apr 2022 |
28 Apr 2022 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in South Korea Updated 28 Apr 2022 |
28 Apr 2022 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Pulmonary-fibrosis in South Korea Updated 28 Apr 2022 |
28 Apr 2022 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Renal-failure in South Korea Updated 28 Apr 2022 |
28 Apr 2022 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Zika-virus-infection in South Korea Updated 28 Apr 2022 |
09 Mar 2018 | Patent Information | Future Medicine has patent protection for adenosine A3 antagonists in South Korea, USA, Australia, China, India, Europe, Japan and Canada [1] Updated 09 Mar 2018 |
09 Mar 2018 | Phase Change - Preclinical | Preclinical trials in Asthma in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018 |
09 Mar 2018 | Phase Change - Preclinical | Preclinical trials in Cancer in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018 |
09 Mar 2018 | Phase Change - Preclinical | Preclinical trials in Chronic obstructive pulmonary disease in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018 |
09 Mar 2018 | Phase Change - Preclinical | Preclinical trials in Glaucoma in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018 |
09 Mar 2018 | Phase Change - Preclinical | Preclinical trials in Middle East respiratory syndrome coronavirus in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018 |
09 Mar 2018 | Phase Change - Preclinical | Preclinical trials in Non-alcoholic steatohepatitis in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018 |
09 Mar 2018 | Phase Change - Preclinical | Preclinical trials in Pulmonary fibrosis in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018 |
09 Mar 2018 | Phase Change - Preclinical | Preclinical trials in Renal failure in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018 |
09 Mar 2018 | Phase Change - Preclinical | Preclinical trials in Zika virus infection in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018 |
References
-
Future Medicine - Patents. Internet-Doc 2018;.
Available from: URL: http://www.futuremedicine.co.kr/en/about/property.html
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG